This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Exosomes Europe
Nov-Dec 2026
Dates and location to be announced
Menu
Key Sessions
Dr. Maureen Merrifield
Regulatory pathway consideration for the licensure of Exosome Therapeutics
Rion Inc.
Tali Kizhner
Unlocking the Regenerative Power of Natural Exosomes
NurExone Biologic
keyboard_arrow_right

Conference Day 1 (4/11/25) - Amsterdam CET

search
Conference Day 1 (4/11/25) - Amsterdam CET
search
Showing 1 of 1 Streams
08:30 - 09:00
Registration & Coffee
Taming the Tiny Giants: Scaling Exosome Production & Purification
Showing 1 of 1 Streams
09:00 - 09:10
Chair's Opening Remarks
  • Konstantin Glebov - Managing Director, Exosome Consulting
09:10 - 09:40
Scaling up production of extracellular vesicles – next step towards clinical therapies against Parkinson‘s disease
  • Augustas Pivoriunas - Co-Founder & CSO, Exosomica
09:40 - 10:10
Early identification of critical manufacturing parameters to de-risk Extracellular Vesicles production
  • Andreia Silva - Head of Research, Exogenus Therapeutics
10:10 - 10:40
Extracellular Vesicles: Accelerating your Path from Benchtop to IND & Beyond
  • Characterization: the keystone to advance EV Therapeutics
  • Clinical manufacturing: Highly-efficient cGMP manufacture
  • Xcite® EV Engineering Platform - available to license
  • Davide Zocco - Senior Director, Commercial Development, Lonza
  • Marcos Langtry - Director, Commercial Development, CGT, Lonza
Showing 1 of 1 Streams
10:40 - 11:20
Morning Networking Break
Taming the Tiny Giants: Scaling Exosome Production & Purification
Showing 1 of 1 Streams
11:20 - 11:50
Purity at Scale: Optimizing Exosome DSP
  • Patrícia Pereira Müller Aguilar - Senior Scientist and Research Group Lead, acib GmbH
Harnessing Nature's Nanoparticles: Exosomes in Regeneration & Therapy
Showing 1 of 1 Streams
11:50 - 12:20
Reversible Immortalization Facilitates the Large-Scale Production of IL10-Enriched Exosomes for Osteoarthritis Therapy
  • Weiming Lai - Dr.Med Candidate, University Heidelberg - Institute of Anatomy and Cell Biology
12:20 - 12:50
Unlocking the Regenerative Power of Natural Exosomes
  • Exosomes in regenerative medicine
  • Challenges throughout manufacturing
  • Exosomes as a drug delivery tool
    • Transition to the Clinic: case study -ExoPTEN - NurExone’s lead product for acute spinal cord injury (SCI)
  • Tali Kizhner - RD Director, NurExone Biologic
Showing 1 of 1 Streams
12:50 - 13:50
Networking Lunch in Exhibit Hall
Harnessing Nature's Nanoparticles: Exosomes in Regeneration & Therapy
Showing 1 of 1 Streams
13:50 - 13:55
Chairperson's Afternoon Remarks
  • Patrícia Pereira Müller Aguilar - Senior Scientist and Research Group Lead, acib GmbH
13:55 - 14:25
The Unusual Suspects: Exploring Diverse Exosome Sources
  • Spencer Marsh - Chief Scientific Officer, Tiny Cargo Company
Characterization & Ensuring Quality Manufacturing
Showing 1 of 1 Streams
14:25 - 15:25
PANEL DISCUSSION: Charting the Course for Standardization: Agreeing on Exosome Quality Metrics
  • Key parameters for release criteria and quality control.
  • The role of advanced characterization (e.g., single vesicle analysis) in ensuring consistency.
    • Establishing robust assays for EV products
  • Pathways towards community consensus on standardized methods.
    • How standardisation can facilitate regulatory approval & industry evolution
  • Patrícia Pereira Müller Aguilar - Senior Scientist and Research Group Lead, acib GmbH
  • Davide Zocco - Senior Director, Commercial Development, Lonza
  • Rajeev Tawar - Associate Director, Vector and Analytical Development, Evox Therapeutics
  • Clément Bonamy - Head of R&D Platform, Everzom
Showing 1 of 1 Streams
15:25 - 16:05
Afternoon Networking Break
Navigating the Path to Patients: Regulatory Hurdles & Early Learnings
Showing 1 of 1 Streams
16:05 - 16:35
Challenges in Clinical Translation for MSC Evs
  • Bernd Giebel - Professor for Translational Extracellular Vesicle Research at University Hospital Essen and Co-Founder & CSO, Exosla Therapeutics
16:35 - 17:05
Regulatory pathway consideration for the licensure of Exosome Therapeutics
  • Rion background PEP exosome product
  • Chemistry manufacturing and control of exosomes
  • Pre-clinical regulatory strategy for exosomes
  • Clinical trial progression of exosomes
  • Interacting with regulatory bodies to progress the exosome field
  • Dr. Maureen Merrifield - Chief Regulatory Officer, Rion Inc.
17:05 - 17:10
Chair's Closing Remarks
  • Patrícia Pereira Müller Aguilar - Senior Scientist and Research Group Lead, acib GmbH
Showing 1 of 1 Streams
17:10 - 18:10
Drinks & Networking Reception
NextConference Day 2 (5/11/25)
Choose Day